Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Page 1 of 7312345...102030...Last »

Ultragenyx Seizure Drug Flunks Phase II Test

Shares of Ultragenyx Pharmaceuticals were down after the company announced its Phase II drug UX007 to treat seizures failed to meet trial goals.

Read More »

GSK and Regeneron to mine gene data

GlaxoSmithKline and Regeneron Pharmaceuticals are embarking on a joint project with UK Biobank to hunt for new clues linking genes and disease.

Read More »

Novartis heart drug serelaxin fails study

Novartis’ heart failure drug serelaxin flopped in a late-stage trial by not cutting cardiovascular death or slowing disease progression, marking the likely demise of a drug hopeful the Swiss firm had promoted as a potential blockbuster.

Read More »

Breast cancer drug combo succeeds key study

Eli Lilly and Co.’s combination of its experimental breast cancer drug abemaciclib and another widely used treatment slowed disease progression.

Read More »

Nektar’s opioid painkiller succeeds in key study

Nektar Therapeutics said its experimental opioid succeeded in a key late-stage study.

Read More »

Catalyst’s neuromuscular drug succeeds in study

Catalyst Pharmaceuticals Inc.’s experimental drug to treat patients with a severe form of myasthenia gravis, a rare neuromuscular disease, met the main goals of a study.

Read More »

FDA Grants Orphan Drug Designation to CSRA’s DynPort Vaccine Company for Plague Vaccine

DynPort’s clinical stage recombinant Yersinia pestis rF1V plague vaccine to benefit from FDA Orphan Drug Designation FALLS CHURCH, Va., March 8, 2017 /PRNewswire/ — CSRA Inc. (NYSE: CSRA) today announced that a plague vaccine being developed by its subsidiary, DynPort Vaccine Company LLC (DVC), was granted Orphan Drug Designation from the U.S. Food and Drug Administration […]

Read More »

Precision Medicine: What Is It And Why Now?

Nearly two decades ago, the promise of precision medicine began making its mark on the pages of medical journals – along with speculation that “therapy with the right drug at the right dose in the right patient” – would define the future of medical treatment.

Read More »

Latest Dupixent eczema drug tests positive

Sanofi and Regeneron said results from a one-year test of Dupixent aimed at adults with eczema or moderate-to-severe atopic dermatitis had been positive.

Read More »

Guselkumab Outperforms Humira In Study

Study data showed patients treated with guselkumab experienced significantly greater improvements compared with the anti-TNF-alpha treatment Humira.

Read More »

Chi-Med Shows Off Phase III Cancer Drug Data

Chi-Med’s fruquintinib met all main endpoints in a Phase III trial as a third-line treatment in patients with locally advanced or metastatic colorectal cancer.

Read More »

PTC abandons cystic fibrosis drug after trial failure

PTC Therapeutics Inc. said it would stop developing its cystic fibrosis drug after it failed to meet the main goal of a late-stage study.

Read More »

Roche drug cocktail cuts breast cancer deaths

Roche’s bid to shield its lucrative oncology franchise from generics got a lift from a trial showing a new drug cocktail kept breast cancer patients alive longer.

Read More »

Kite’s cancer drug clears main study goal

Kite Pharma Inc.’s experimental CAR T-cell therapy was highly effective in treating aggressive non-Hodgkin’s lymphoma, meeting the main goal of a key study.

Read More »

Accera’s Alzheimer’s drug trial fails

Nestle SA-backed Accera Inc.’s experimental Alzheimer’s drug failed a late-stage study in the pursuit of an effective treatment for the rampant mind-wasting disease.

Read More »

Hepatocytes in the Drug Development Pipeline

Lonza is hosting a free 60-minute webinar on March 21, 2017, titled “Hepatocytes in the Drug Development Pipeline.”

Read More »

TrialScope Launches Trial Results Summaries Portal

TrialScope, the global leader in clinical trial transparency and compliance solutions, announced the launch of the Trial Results Summaries Portal. Through the publicly accessible website, clinical trial sponsors can inform and educate trial participants and the general public about trial results through a non-promotional and unbiased venue.

Read More »

New drugs needed to fight priority pathogens

New antibiotics need to be developed urgently to combat 12 bacteria families, “priority pathogens” that are the greatest threats to human health, WHO says.

Read More »

La Jolla’s blood pressure drug clears key study

La Jolla Pharmaceutical Co.’s shares surged after the company said its drug to treat low blood pressure succeeded in a key trial.

Read More »

Cempra’s bacterial skin infection drug clears study

Cempra Inc. said its experimental oral drug to treat acute bacterial skin infections cleared a late-stage study.

Read More »

Page 1 of 7312345...102030...Last »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

February 2017 Focus: Top 10 Pipelines, Agenda 2017 and more!


Ad Right Bottom

Password Reset
Please enter your e-mail address. You will receive a new password via e-mail.

Main Navigation